Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
8.25
USD
+4.30%
+8.70%
+22.22%
This article is reserved for members
Not a member ?
Free registration
Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating
May. 14
MT
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15
May. 14
MT
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
May. 13
DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment
May. 13
MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug
May. 13
MT
Transcript : Fulcrum Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
May. 13
DJ
Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy in The Lancet Neurology
May. 08
CI
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer
Mar. 18
MT
Fulcrum Therapeutics, Inc. Announces Executive Changes
Mar. 18
CI
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index
Mar. 17
CI
GSK: Dr Jeannie Lee joins the Board of Directors
Feb. 29
CF
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating
Feb. 28
MT
Transcript : Fulcrum Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Feb. 27
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 27
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 27
CI
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating
Jan. 25
MT
Transcript : Fulcrum Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer
Nov. 01
MT
Fulcrum Therapeutics, Inc. Announces Resignation of Mel Hayes as Chief Operating Officer
23-10-02
CI
Fulcrum Therapeutics Completes Patient Enrollment for Phase 3 Study of Losmapimod
23-09-07
MT
North American Morning Briefing : Nasdaq Futures -2-
23-08-24
DJ
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5
23-08-23
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Companyâs clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
More about the company
Last Close Price
8.25
USD
Average target price
14.25
USD
Spread / Average Target
+72.73%
Consensus
1st Jan change
Capi.
+22.22% 513M +29.77% 49.46B +1.00% 42.58B +49.56% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B +24.01% 12.1B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**